Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice
Open Access
- 11 March 2016
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 7 (1) , 10981
Abstract
Carbohydrate-based infusion solutions are widely used in the clinic. Here we show that co-administration of phosphorodiamidate morpholino oligomers (PMOs) with glucose enhances exon-skipping activity in Duchenne muscular dystrophy (DMD)mdxmice. We identify a glucose–fructose (GF) formulation that potentiates PMO activity, completely corrects aberrantDmdtranscripts, restores dystrophin levels in skeletal muscles and achieves functional rescue without detectable toxicity. This activity is attributed to enhancement of GF-mediated PMO uptake in the muscle. We demonstrate that PMO cellular uptake is energy dependent, and that ATP from GF metabolism contributes to enhanced cellular uptake of PMO in the muscle. Collectively, we show that GF potentiates PMO activity by replenishing cellular energy stores under energy-deficient conditions inmdxmice. Our findings provide mechanistic insight into hexose-mediated oligonucleotide delivery and have important implications for the development of DMD exon-skipping therapy.Keywords
This publication has 37 references indexed in Scilit:
- Metabolic homeostasis of the heartJournal of General Physiology, 2012
- Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation studyThe Lancet, 2011
- Systemic Administration of PRO051 in Duchenne's Muscular DystrophyNew England Journal of Medicine, 2011
- One-year Treatment of Morpholino Antisense Oligomer Improves Skeletal and Cardiac Muscle Functions in Dystrophic mdx MiceMolecular Therapy, 2011
- The physiological regulation of glucose flux into musclein vivoJournal of Experimental Biology, 2011
- Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomerProceedings of the National Academy of Sciences, 2008
- Transvascular delivery of small interfering RNA to the central nervous systemNature, 2007
- Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathologyNature Medicine, 2006
- Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatmentEMBO Reports, 2004
- Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophyThe Journal of Gene Medicine, 2002